{"subsection_name": null, "pub_date": "2011-10-19T09:01:28Z", "byline": {"original": "By BRUCE JAPSEN", "person": [{"lastname": "JAPSEN", "organization": "", "rank": 1, "role": "reported", "firstname": "Bruce"}]}, "abstract": "The company said it would divide into two publicly traded entities.", "word_count": 749, "print_page": null, "news_desk": null, "snippet": "The company said it would divide into two publicly traded entities.", "multimedia": [], "source": "The New York Times", "blog": [], "keywords": [{"name": "subject", "value": "Medical Devices", "rank": "4"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "3"}, {"name": "persons", "value": "White, Miles D", "rank": "2"}, {"name": "organizations", "value": "Abbott Laboratories", "rank": "5"}, {"name": "type_of_material", "value": "News", "rank": "1"}, {"name": "unknown", "value": "Abbott Laboratories|ABT|NYSE", "rank": "6"}], "type_of_material": "Blog", "lead_paragraph": "Updated: 12:45 p.m. Abbott Laboratories said on Wednesday it would separate into two publicly traded companies, one focused on medical devices like heart stents and the other in what it called \"research-based pharmaceuticals,\" such as its blockbuster rheumatoid arthritis drug Humira.", "web_url": "http://prescriptions.blogs.nytimes.com/2011/10/19/abbott-plans-to-split-into-two-companies/", "section_name": "Health", "headline": {"main": "Abbott Plans to Split Into Two Companies", "kicker": "Prescriptions"}, "slideshow_credits": null, "_id": "4fd3a1a28eb7c8105d8e880c", "document_type": "blogpost"}